On March 14, 2025, the Leadership Oversight Advisory Group and the Co-Leads from each task force met to debrief and begin the next steps in identifying strategic priorities for short-term ...
Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback